中华医学杂志（英文版）2025，Vol.138Issue(5)：531-539,9.DOI:10.1097/CM9.0000000000003371
Efficacy and safety of immune checkpoint inhibitors in the treatment of recurrent or metastatic nasopharyngeal carcinoma:A systematic review and meta-analysis
Efficacy and safety of immune checkpoint inhibitors in the treatment of recurrent or metastatic nasopharyngeal carcinoma:A systematic review and meta-analysis
Zhixin Yu 1Shaodong Hong 2Hui Yu 2Xuanye Zhang 2Zichun Li 1Ping Chen 1Yixin Zhou1
作者信息
- 1. State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangzhou,Guangdong 510000,China||Department of VIP Region,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong 510000,China
- 2. State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangzhou,Guangdong 510000,China||Department of Medical Oncology,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong 510000,China
- 折叠
摘要
关键词
Nasopharyngeal carcinoma/Immune checkpoint inhibitor/Immunotherapy/First-line therapy/Later-line therapy/Meta-analysisKey words
Nasopharyngeal carcinoma/Immune checkpoint inhibitor/Immunotherapy/First-line therapy/Later-line therapy/Meta-analysis引用本文复制引用
Zhixin Yu,Shaodong Hong,Hui Yu,Xuanye Zhang,Zichun Li,Ping Chen,Yixin Zhou..Efficacy and safety of immune checkpoint inhibitors in the treatment of recurrent or metastatic nasopharyngeal carcinoma:A systematic review and meta-analysis[J].中华医学杂志（英文版）,2025,138(5):531-539,9.
